H35.3194 Nonexudative age-related macular degeneration, unspecified eye, advanced atrophic with subfoveal involvement

Name of the Condition

• Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Advanced Atrophic with Subfoveal Involvement

Summary

Nonexudative age-related macular degeneration (AMD) is a chronic eye condition affecting the macula, the central part of the retina responsible for sharp central vision. It is characterized by gradual macular degeneration without fluid leakage or bleeding, leading to blurred or reduced vision. This form of AMD is also commonly referred to as "dry AMD." The unspecified eye and advanced atrophic stage with subfoveal involvement indicate that the condition is not localized to a specific eye and has progressed to a late stage where atrophy (thinning) of the retinal tissue occurs beneath the fovea, the central part of the macula.

Causes

The exact cause of nonexudative AMD is not fully understood, but it involves the degeneration of retinal cells and the accumulation of drusen (yellow deposits) under the retina. Oxidative stress and inflammation in retinal tissues are also believed to contribute to the condition.

Risk Factors

• Increasing age, especially over 50.
• Family history of macular degeneration.
• Smoking and tobacco use.
• Obesity and high cholesterol.
• Lack of exercise and poor diet lacking antioxidants and zinc.

Symptoms

• Blurred or reduced central vision.
• Difficulty recognizing faces or reading.
• Need for brighter lighting when working or reading.
• Haziness in overall vision.
• Distortion or loss of central vision due to advanced atrophy.

Diagnosis

Diagnosis involves a comprehensive eye examination, including dilation, to assess the macula. Optical coherence tomography (OCT) is used to visualize retinal layers and detect atrophy, while a fluorescein angiography may be performed to evaluate subfoveal involvement. An Amsler grid test detects vision distortions, and visual acuity testing assesses the extent of vision loss.

Treatment Options

Treatment focuses on managing symptoms and slowing progression. Nutritional supplements (e.g., vitamins C, E, zinc, and lutein) may be recommended. Low-vision aids, such as magnifiers or specialized lighting, help with daily tasks. In some cases, anti-VEGF injections or photodynamic therapy may be considered, though these are more common in exudative AMD. Regular monitoring is essential to track changes.

Prognosis and Follow-Up

Prognosis depends on the extent of atrophy and vision loss. Advanced atrophic AMD with subfoveal involvement often leads to significant central vision impairment, though peripheral vision remains intact. Regular follow-up with an ophthalmologist is crucial to monitor progression and adjust management. Low-vision rehabilitation may be necessary to maintain independence.

Complications

• Severe central vision loss, affecting daily activities like reading or driving.
• Increased risk of developing exudative (wet) AMD in the same or fellow eye.
• Emotional and psychological impact due to vision impairment.

Lifestyle & Prevention

• Quit smoking and avoid tobacco exposure.
• Maintain a healthy diet rich in antioxidants, omega-3 fatty acids, and leafy greens.
• Exercise regularly to support overall health.
• Protect eyes from UV light with sunglasses.
• Monitor vision changes using an Amsler grid and report new distortions promptly.

When to Seek Professional Help

Seek immediate medical attention if you experience sudden vision changes, such as blurriness, distortion, or dark spots in central vision. Regular eye exams are recommended for those over 50 or with risk factors, even if symptoms are mild.

Tips for Medical Coders

Document the eye (unspecified) and specify "advanced atrophic with subfoveal involvement" to accurately reflect the condition. Ensure clinical notes support the advanced stage and subfoveal location, as these details are critical for coding. Use H35.3194 for this specific presentation.